The global vaccines market was valued at USD 90.28 billion in 2023 and is expected to grow from USD 87.57 billion in 2024 to USD 159.28 billion by 2032, reflecting a CAGR of 7.8% during the forecast period. In North America, the vaccines market is projected to expand from USD 37.57 billion in 2023 to USD 38.75 billion in 2024.

The vaccines market is witnessing significant growth driven by increasing awareness of immunization, rising prevalence of infectious diseases, and continuous advancements in biotechnology. The global vaccines market encompasses a wide range of products including prophylactic and therapeutic vaccines aimed at preventing diseases such as influenza, hepatitis, HPV, and COVID-19, among others. Government initiatives, public health campaigns, and collaborations between pharmaceutical companies and global health organizations are further fueling market expansion. In addition, the vaccines market is benefiting from innovations in mRNA technology, recombinant vaccines, and novel delivery systems. As healthcare infrastructure improves across emerging economies, the vaccines market is expected to see enhanced accessibility and coverage, contributing to sustained growth.

Continue reading for more details:

**https://www.fortunebusinessinsights.com/industry-reports/vaccines-market-101769**

Market Segmentation

• By Type: Includes inactivated vaccines, live attenuated vaccines, subunit/conjugate vaccines, mRNA vaccines, and toxoid vaccines.
• By Disease Indication: Covers influenza, HPV, COVID-19, hepatitis, pneumococcal, meningococcal, DTP, and others.
• By Age Group: Segments include pediatric, adolescent, adult, and geriatric populations, all contributing to the vaccines market.
• By Route of Administration: Intramuscular, subcutaneous, oral, and intradermal routes play critical roles in the vaccines market.
• By End User: Includes hospitals, clinics, vaccination centers, and public health agencies driving demand in the vaccines market.

List Of Key Companies Profiled in Vaccines Market:

• GlaxoSmithKline plc. (U.K.)
• Sanofi (France)
• Pfizer Inc. (U.S.)
• Merck & Co., Inc. (U.S.)
• Novartis AG (Switzerland)
• Emergent BioSolutions, Inc. (U.S.)
• CSL Limited (Australia)
• Inovio Pharmaceuticals, Inc. (U.S.)